We have located links that may give you full text access.
[Perampanel in pharmacotherapy of focal epilepsy: the efficacy and tolerability in routine clinical practice].
AIM: To analyze the efficacy and tolerability of the innovative drug perampanel (PER) as add-on treatment of focal epilepsy in patients older than 12 years.
MATERIAL AND METHODS: Forty-six patients with focal epilepsy, aged from 12 to 63 years, mean age 31.7 years, were studied.
RESULTS AND CONCLUSION: A decrease in the frequency of all types of seizures by >50% was noted in 46,5% of patients. Stopping of all types of seizures was found in 25.6% of patients, i.e. in every fourth patient, stopping of secondary-generalized seizures in 39.5%. Adverse effects (AE) were identified in 13 (28.2%) of patients, including aggressiveness - 6 (13.0%); other AE were less frequent (<10%): sleepiness (8.7%), dizziness (4.3%), postural instability (4.3%), irritability (4.3%). PER was withdrawn in 3 (6.5%) patients due to AE. Mean effective dose was 6 mg/day. Quality-of-life improved in the majority of patients (71.7%).
MATERIAL AND METHODS: Forty-six patients with focal epilepsy, aged from 12 to 63 years, mean age 31.7 years, were studied.
RESULTS AND CONCLUSION: A decrease in the frequency of all types of seizures by >50% was noted in 46,5% of patients. Stopping of all types of seizures was found in 25.6% of patients, i.e. in every fourth patient, stopping of secondary-generalized seizures in 39.5%. Adverse effects (AE) were identified in 13 (28.2%) of patients, including aggressiveness - 6 (13.0%); other AE were less frequent (<10%): sleepiness (8.7%), dizziness (4.3%), postural instability (4.3%), irritability (4.3%). PER was withdrawn in 3 (6.5%) patients due to AE. Mean effective dose was 6 mg/day. Quality-of-life improved in the majority of patients (71.7%).
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app